Welcome to the Pfizer Sponsored Breakfast Symposium
Smarter Data for Smarter Care: How Artificial Intelligence is Reshaping Real-World Evidence in HR+/HER2- mBC.
Pfizer is pleased to welcome Breast Cancer Trials attendees to an interactive and informative symposium centered on artificial intelligence in metastatic breast cancer. The session is designed to enable discussion amongst the audience and the highly experienced panelists. Click here to find out more.
Chaired by Associate Professor Louise Nott, the symposium will feature presentations from renowned specialists Professor Karin Verspoor and Professor Adam Brufsky.
Agenda Highlights:
- Hype and Hope for Artificial Intelligence in Oncology: Reflection on the artificial intelligence revolution and its implications for clinical practice.
- Advancing the Application of Artificial Intelligence in Healthcare: Making complex data more accessible and actionable for medical professionals.
- RWE and the Application of Artificial Intelligence Using the Flatiron Database: HR+/HER2- mBC with CDK4/6 inhibitors, now and in the future.
- Panel Discussion with Audience Q&A.
Don’t miss this opportunity to gain expert insights, explore real-world clinical considerations, and connect with peers in the oncology community. We look forward to seeing you there!
Meet our Guest Speakers
We are pleased to introduce the following speakers at the Pfizer-sponsored Breakfast Symposium.
Louise Nott
T&EC Day Guest Speaker
Louise Nott
T&EC Day Guest Speaker
Clinical Associate Professor Louise Nott is an experienced medical oncologist at Icon Cancer Centre Hobart. She completed her Bachelor of Medicine and Bachelor of Surgery (Honours) at the University of Tasmania and became a fellow of the Royal Australasian College of Physicians (FRACP) in 2006. A/Prof Nott undertook a fellowship at The Queen Elizabeth Hospital in Adelaide before returning to Hobart in 2007 to work as a medical oncology staff specialist at Royal Hobart Hospital.
A/Prof Nott is widely published and has acted as principal and sub-investigator on over 50 oncology clinical trials across industry, collaborative, and academic sectors. She holds an honorary associate position at Sydney Medical School and is a university associate with the Menzies Research Institute in Tasmania. A/Prof Nott has extensive experience in treating a wide variety of cancers and is dedicated to providing excellence in cancer care for her patients and their loved ones.
She is also Icon Group’s Director of Medical Oncology (AU/NZ), providing exceptional clinical leadership across Icon’s Australia and New Zealand centres.
Karin Verspoor
Symposium Guest Speaker
Karin Verspoor
Symposium Guest Speaker
Professor Karin Verspoor is Dean of the School of Computing Technologies at RMIT University in Melbourne, Australia.
Karin's research primarily focuses on the use of artificial intelligence methods to enable biological discovery and clinical decision support, through the extraction of information from clinical texts and the biomedical literature and machine learning-based modelling.
Karin held previous posts as Director of Health Technologies and Deputy Head of the School of Computing and Information Systems at the University of Melbourne, as the Scientific Director of Health and Life Sciences at NICTA Victoria Research Laboratory, at the University of Colorado School of Medicine, and at Los Alamos National Laboratory.
She is also the Victorian Node lead and co-founder of the Australian Alliance for Artificial Intelligence in Health.
Industry experience:
- Intelligenesis/Webmind Corporation (New York, NY, USA)
- Applied Semantics (Los Angeles, CA, USA)
- Los Alamos National Laboratory (Los Alamos, NM, USA)
- National ICT Australia (Melbourne, VIC, Australia)
Adam Brufsky
International Guest Speaker
Adam Brufsky
International Guest Speaker
Dr Brufsky is board-certified in internal medicine and medical oncology by the American Board of Internal Medicine and is an active member of the American Society of Clinical Oncology and the American Association for Cancer Research.
He has published numerous abstracts and research articles in leading journals, including the Journal of Clinical Investigation, Journal of Clinical Oncology and Lancet.
Dr Brufsky is principal investigator on a number of research grants funded by the National Institutes of Health, the Susan G. Komen Foundation and the U.S. Army Breast Cancer Research Program.
He is currently the principal investigator of the Pittsburgh Breast Cancer Consortium, a U.S. Department of Defense-funded program to increase community access to innovative clinical trials for the treatment of metastatic breast cancer, as well as a number of other breast cancer studies.
Dr Brufsky's training responsibilities include teaching attending physicians for the University of Pittsburgh Cancer Institute and the University of Pittsburgh School of Medicine and School of Nursing.
Additionally, he serves as director of the integrated life sciences selective courses, neoplastic diseases course at the University of Pittsburgh Medical Center.
Dr Brufsky received his medical degree and doctorate from the University of Connecticut School of Medicine. He completed his residency in internal medicine at Brigham and Women's Hospital, Harvard Medical School, and a fellowship in medical oncology and bone marrow transplantation at the Dana-Farber Cancer Institute.
Prior to joining the University of Pittsburgh, Dr Brufsky served as an associate physician and instructor in medicine at Harvard Medical School.